<DOC>
	<DOCNO>NCT02668367</DOCNO>
	<brief_summary>This single center , sequential-cohort , double-blind , placebo-controlled , multiple ascend dose ( MAD ) , 7-day treatment period study healthy subject .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study Multiple Ascending Doses BTA-C585 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . Healthy men woman ; 2 . Age 18 60 year , inclusive ; 3 . Weight â‰¥ 50 kg Body Mass Index ( BMI ) 19 32 , inclusive ; 4 . Female subject must nonchildbearing potential ; 5 . Male subject must agree use double barrier method birth control ; 6 . Signed informed consent form ( ICF ) prior study procedure . 1 . Current recent ( within 14 day Day 0 ) bacterial viral infection ; 2 . Positive result screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody ; 3 . Clinically significant abnormality note ECG ; 4 . Safety laboratory abnormality ; 5 . Regular use medication , prescription nonprescription ; 6 . Poor vein access fear venipuncture sight blood ; 7 . Major surgery , significant recent injury trauma within 30 day ; 8 . Received investigational drug vaccine within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Viral Diseases</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Paramyxoviridae Infections</keyword>
	<keyword>RSV</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
	<keyword>Aviragen Therapeutics , Inc .</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>